Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018, University of Glasgow
Existing treatment could be used for common ‘untreatable’ form of lung cancer
Credit: University of Glasgow

A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

The new findings, published today in Science Translational Medicine and led by the University of Glasgow, suggest that a large number of patients could benefit from this – a second generation EGFR inhibitor (a drug that slows down or stops cell growth) – if used in combination with additional therapies.

The scientists hope the treatment could be deployed for use in patients in the near future, given it is already approved for the treatment of other cancers.

Cancers of the kill more people worldwide than cancers of any other organ, more than 1.5m people per annum. The largest subtype of lung , which the researchers studied, is adenocarcinoma.

One third of adenocarcinoma cancers carry a mutant gene called KRAS, which the researchers show requires the activity of any of four "EGFR/ERBB growth factor receptors' to drive cell proliferation. There are presently no KRAS-inhibiting drugs available for treatment of these cancers and first generation EGFR drugs have failed to show any benefit to this form of cancer.

However, the scientists in this study found that, unlike first-generation EGFR inhibitors, one particular second-generation EGFR inhibitor – a multi-ERBB inhibitor—blocked the proliferation of KRAS-mutant lung cancer cells in lab studies and actually prevented the formation of KRAS-driven lung cancers in mice.

Lead author Dr. Daniel Murphy, Senior Lecturer at the University's Institute of Cancer Sciences and a scientist at Glasgow's Cancer Research UK Beatson Institute, said: "There is a pressing need to develop alternative strategies for more effective treatment of KRAS‐driven lung cancer, and this is a promising breakthrough which we hope could benefit patients soon.

"The inhibitor we studied – a multi-ERBB inhibitor – helped sensitise tumours and was of therapeutic benefit when used in combination with another cancer drug called Trametinib, resulting in a clear extension of lifespan.

"Based on our findings, we hope with the KRAS-driven form of lung cancer may in future benefit from inclusion of this inhibitor in their treatment plan."

Unwanted side-effects of these drugs on normal tissues remains a concern, however, new strategies to limit delivery of these drugs to the tumour site could reduce such side-effects and greatly improve the utility of this class of therapeutics.

Dr. Catherine Pickworth of Cancer Research UK said: "These findings in the lab have revealed a new role for four related molecules in a particular type of lung cancer. Furthermore, by targeting these molecules in mice the researchers found this increased the effectiveness of an existing lung cancer drug.

"We now need further studies to work out if this holds true in people and what the side effects might be. We urgently need new and better ways to treat lung cancer, a disease where survival has remained stubbornly low."

Dr. Alan McNair from the Scottish Government Chief Scientist Office said: "We are delighted to have been a partner in funding this important research. It is through collaborations of this type that effective new approaches to the treatment of lung cancer are likely to be developed."

Ian Jarrold, Head of Research at the British Lung Foundation, said: "Lung cancer is the third most common cancer in the UK, so research into new treatments is vital. This is a promising finding, which could potentially help thousands of people a year, and we are delighted to have been involved in funding the project. More research is needed now to determine if this combination of treatments, which has proven successful in a laboratory setting, is safe and effective in people with ."

The paper, "The ERBB network facilitates KRAS-driven lung tumorigenesis," is published in Science Translational Medicine.

Explore further: Three hits to fight lung cancer

More information: Björn Kruspig et al. The ERBB network facilitates KRAS-driven lung tumorigenesis, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aao2565

Related Stories

Three hits to fight lung cancer

January 1, 2016
Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment. (New therapies ...

Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer

January 7, 2014
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most ...

Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

September 8, 2017
Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumours, thereby potentially improving patients' survival.

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

Even smokers may benefit from targeted lung cancer treatments

December 13, 2017
Smokers are less likely than non-smokers to have lung cancers caused by targetable genetic changes. But a study published this week in the journal Clinical Cancer Research shows that when they do, smokers benefit just as ...

Researchers develop new strategy to target KRAS mutant cancer

September 14, 2017
Although KRAS is one of the major oncogenes associated with aggressive cancers, drugs designed to block KRAS function have not been able to halt cancer progression in a clinical setting. Until now, KRAS has remained infamously ...

Recommended for you

A molecule for fighting muscular paralysis

November 19, 2018
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Although no treatment currently exists, researchers from the University of Geneva (UNIGE), ...

Scientists trained a computer to classify breast cancer tumors

November 19, 2018
Using technology similar to the type that powers facial and speech recognition on a smartphone, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have trained a computer to analyze breast ...

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

Use genetic data to predict the best time of day to give radiotherapy to breast cancer patients, say researchers

November 19, 2018
A new clinical study led by the University of Leicester and conducted in the HOPE clinical trials facility at Leicester's Hospitals has revealed the pivotal role that changing the time of day that a patient receives radiotherapy ...

New dual-action cancer-killing virus

November 19, 2018
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

New blood test detects early stage ovarian cancer

November 19, 2018
Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer—a disease which kills over 1000 Australian women and 150,000 globally each ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.